Keyphrases
Acute Lymphoblastic Leukemia
97%
Pediatric Acute Lymphoblastic Leukemia
35%
L-asparaginase
31%
Childhood Acute Lymphoblastic Leukemia
28%
Pediatric
25%
Dutch
24%
Leukemia Patients
23%
Methotrexate
19%
Pediatric Patients
18%
Minimal Residual Disease
18%
Netherlands
16%
Leukemia
15%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
15%
Children with Cancer
14%
BCP-ALL
13%
Oncology
13%
Infant Acute Lymphoblastic Leukemia
13%
Pediatric Leukemia
11%
Paediatric B-cell Precursor Acute Lymphoblastic Leukaemia
11%
Event-free Survival
10%
KMT2A
10%
Vincristine-induced Peripheral Neuropathy
8%
IKZF1 Deletion
8%
Oral mucositis
8%
Acute Lymphoblastic Leukemia Cells
8%
Confidence Interval
8%
IKZF1
8%
Working Diagnosis
8%
Media Risk
8%
Pediatric Oncology
7%
Overall Survival
7%
Population Pharmacokinetics
7%
Ponte
7%
Improved Survival
7%
Escherichia Coli
7%
Young Adolescents
7%
Childhood Cancer
6%
High Risk
6%
Pharmacokinetics
6%
Peripheral Neuropathy
6%
Bone Mineral Density
6%
5-year Survival
6%
Pegaspargase
6%
Acute Myeloid Leukemia
6%
Pediatric Cancer Patients
6%
Older Adults
6%
Leucovorin
6%
Erwinia Asparaginase
6%
Survivors
5%
Risk Factors
5%
Asparaginase Activity
5%
Dexamethasone Treatment
5%
High-dose Methotrexate (HD-MTX)
5%
Preadolescent children
5%
Newly Diagnosed
5%
Steroid Resistance
5%
Neurobehavior
5%
Leukemia Therapy
5%
Neuroblastoma
5%
Sleep-wake Rhythm
5%
Hydrocortisone
5%
Asparaginase-associated Pancreatitis
5%
PEGylated
5%
Pediatric ALL
5%
Cancer-related Fatigue
5%
Childhood Cancer Survivors
5%
Sleep Problems
5%
Activity Level
5%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Pediatrics
45%
Malignant Neoplasm
24%
B Cell
17%
Minimal Residual Disease
17%
Precursor
15%
Adolescence
15%
Childhood Cancer
15%
Oncology
10%
Leukemia
10%
Disease
10%
Overall Survival
9%
Dexamethasone
8%
Pediatrics Patient
8%
Event Free Survival
8%
High Risk Population
7%
Vincristine
7%
Pediatric Acute Myeloid Leukemia
7%
Randomized Controlled Trial
7%
Ganglioneuroblastoma
6%
Methotrexate
6%
Neuropathy
6%
Acute Myeloid Leukemia
6%
Neoplasm
6%
Maintenance Therapy
6%
Pediatric Cancer
5%
Leukemia Cell
5%
Risk Stratification
5%
Survival Rate
5%
Bone Density
5%
Diagnosis
5%